RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket billAs previously posted and in advance of the US Senate's action against patent thickets, Big Pharma such as Sanofi had 'front-run' this devvelopment by announcing the off-loading of their consumer healthcare divisions, which are heavily protected by patent thickets, in favor of increasingly pronounced investments in biologic therapeutics that target unmet needs and rare diseases in the immunology and oncology spaces.
Today September 25, 2025 - Sanofi seperately announced that it may soon follow in the footsteps of GSK and Johnson & Johnson with the separation of its consumer health unit.
Sanofi has received separate offers from private equity firms PAI Partners and Clayton, Dubilier & Rice for its consumer health business, which could be valued at 15 billion euros ($16.7 billion) or more, Bloomberg reported.
Last year, J&J spun off its consumer health business under the brand name Kenvue, following similar moves by Pfizer and GSK in 2022, making way for significant M&A activity/deals such as Pfizer's acquisition of Seagen for US$43 Billion.
https://www.fiercepharma.com/pharma/private-equity-firms-circle-sanofis-16b-consumer-health-business-potential-deal-nears